Roden D M, Nadeau J H, Primm R K
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232.
Clin Pharmacol Ther. 1988 Jun;43(6):648-54. doi: 10.1038/clpt.1988.90.
Clonidine can produce symptomatic sinus bradycardia or atrioventricular (AV) block in some patients. Electrophysiologic studies have been performed after intravenous clonidine in patients showing such side effects; these have demonstrated variable depression of sinus and AV nodal function. We have evaluated the electrophysiologic and hemodynamic effects of chronic oral treatment with either clonidine (0.2 to 0.5 mg every 12 hours; n = 7) or another centrally active alpha 2-agonist, tiamenidine (0.5 to 1.5 mg every 12 hours; n = 7), in otherwise healthy hypertensive human volunteers. At dosages that modestly lowered diastolic blood pressure, both agents significantly slowed sinus rate and increased the atrial pacing rate producing AV nodal Wenckebach. Clonidine also significantly increased corrected sinus node recovery time and lowered cardiac output while similar (but statistically insignificant) trends were seen with tiamenidine. We conclude that chronic oral treatment with these alpha 2-agonists depresses sinus and AV nodal function in virtually all subjects, including those without manifest conduction system disease.
可乐定在某些患者中可导致症状性窦性心动过缓或房室(AV)传导阻滞。对于出现此类副作用的患者,已在静脉注射可乐定后进行了电生理研究;这些研究表明窦房结和房室结功能存在不同程度的抑制。我们评估了可乐定(每12小时0.2至0.5毫克;n = 7)或另一种中枢活性α2激动剂噻美尼定(每12小时0.5至1.5毫克;n = 7)对健康高血压志愿者进行长期口服治疗后的电生理和血流动力学效应。在适度降低舒张压的剂量下,两种药物均显著减慢窦性心率,并增加导致房室结文氏现象的心房起搏率。可乐定还显著延长校正窦房结恢复时间并降低心输出量,而噻美尼定也出现了类似(但无统计学意义)的趋势。我们得出结论,这些α2激动剂的长期口服治疗几乎会抑制所有受试者的窦房结和房室结功能,包括那些无明显传导系统疾病的受试者。